Clinical trial
Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
NCT00304954 · National Eye Institute (NEI), NIH · Completed
Key facts
| NCT number | NCT00304954 |
|---|---|
| Title | Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration |
| Official title | Treatment of Choroidal Subretinal Neovascularization With Agents Directed Against the Immune Response |
| Acronym | AMDB1 |
| Lead sponsor | National Eye Institute (NEI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Age-Related Macular Degeneration, Choroidal Neovascularization |
| Intervention type | Drug, Other |
| Interventions | Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin |
| Enrollment | 13 |
| Start date | Feb 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Mar 20, 2006 |
| Last update posted | Nov 29, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: